BridgeBio Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BridgeBio Pharma 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BBIO

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. 

CEO
Neil Kumar
CEONeil Kumar
Employees
839
Employees839
Headquarters
Palo Alto, California
HeadquartersPalo Alto, California
Founded
2015
Founded2015
Employees
839
Employees839

BBIO Key Statistics

Market cap
12.98B
Market cap12.98B
Price-Earnings ratio
-17.69
Price-Earnings ratio-17.69
Dividend yield
Dividend yield
Average volume
2.59M
Average volume2.59M
High today
$68.15
High today$68.15
Low today
$66.15
Low today$66.15
Open price
$67.96
Open price$67.96
Volume
2.87M
Volume2.87M
52 Week high
$84.94
52 Week high$84.94
52 Week low
$32.37
52 Week low$32.37

Stock Snapshot

BridgeBio Pharma(BBIO) stock is priced at $66.26, giving the company a market capitalization of 12.98B. It carries a P/E multiple of -17.69.

During the trading session on 2026-05-30, BridgeBio Pharma(BBIO) shares reached a daily high of $68.15 and a low of $66.15. At a current price of $66.26, the stock is +0.2% higher than the low and still -2.8% under the high.

Trading activity shows a volume of 2.87M, compared to an average daily volume of 2.59M.

The stock's 52-week range extends from a low of $32.37 to a high of $84.94.

The stock's 52-week range extends from a low of $32.37 to a high of $84.94.

BBIO News

TipRanks 3d
BridgeBio Wins FDA Priority Review for BBP-418 Therapy

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Simply Wall St 3d
A Look At BridgeBio Pharma Valuation After Raymond James Downgrade On Payer Risk Concerns

Advertisement Analyst downgrade focuses attention on payer risk Raymond James recently downgraded BridgeBio Pharma (BBIO) to Market Perform, highlighting grow...

A Look At BridgeBio Pharma Valuation After Raymond James Downgrade On Payer Risk Concerns

Analyst ratings

92%

of 24 ratings
Buy
91.7%
Hold
8.3%
Sell
0%

People also own

Based on the portfolios of people who own BBIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.